LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lantern Pharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.64−0.03 (-4.05%)
Close on Oct 19, 2026
- Market cap
- $7.97M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
22.6%
3M of 13M shares
Institutional holders
39
12 new, 6 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $200.00K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 975,000 | 7.60% | 13G (passive) amendment | Jun 30, 2026 |
| Cavu Advisors, LLC | 960,026 | 8.58% | 13D (active) amendment | Feb 20, 2026 |
| Ryan M. Lane | 1,322,551 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Leslie W. Kreis | 1,075,952 | 9.98% | 13D (active) amendment | Jun 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LTRN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 842,669 | 6.59% | $3.51M | New | 4.06% |
| CM Management, LLC | 500,000 | 3.91% | $2.09M | +250,000 | 1.39% |
| Vanguard Capital Management LLC | 425,118 | 3.33% | $1.77M | +93,039 | 0.00% |
| Renaissance Technologies LLC | 291,039 | 2.28% | $1.21M | +175,039 | 0.00% |
| BIOS Capital Management, LP | 249,397 | 1.95% | $1.04M | −615,038 | 2.50% |
| Geode Capital Management, LLC | 102,819 | 0.80% | $428.85K | −8,827 | 0.00% |
| Vanguard Fiduciary Trust Co | 49,950 | 0.39% | $208.29K | +343 | 0.00% |
| Citadel Advisors LLC | 47,895 | 0.37% | $199.72K | New | 0.00% |
| Westside Investment Management, Inc. | 47,850 | 0.37% | $199.54K | −2,200 | 0.03% |
| Quadrature Capital Ltd | 39,593 | 0.31% | $165.10K | New | 0.00% |
| NewEdge Advisors, LLC | 27,049 | 0.21% | $112.80K | −350 | 0.00% |
| Horizon Kinetics Asset Management LLC | 25,164 | 0.20% | $104.93K | −1,209 | 0.00% |
| DAVENPORT & Co LLC | 23,814 | 0.19% | $99.30K | – | 0.00% |
| State Street Corp | 23,652 | 0.19% | $98.63K | – | 0.00% |
| BlackRock, Inc. | 22,350 | 0.17% | $93.20K | −22,917 | 0.00% |
| Bank of New York Mellon Corp | 21,301 | 0.17% | $88.83K | – | 0.00% |
| Northern Trust Corp | 17,485 | 0.14% | $72.91K | +1,896 | 0.00% |
| XTX Topco Ltd | 17,415 | 0.14% | $72.62K | New | 0.00% |
| Dimensional Fund Advisors LP | 16,725 | 0.13% | $69.74K | −21,335 | 0.00% |
| UBS Group AG | 16,632 | 0.13% | $69.36K | +6,555 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 39 | 3M | 22.6% | 12 / 9 | 8 / 6 | 2M | 1M |
| Q1 2026 | 33 | 2M | 16.4% | 5 / 9 | 9 / 3 | 0M | 0M |
| Q4 2025 | 33 | 2M | 17.8% | 6 / 6 | 9 / 4 | 0M | 0M |
| Q3 2025 | 31 | 2M | 17.9% | 3 / 9 | 8 / 7 | 0M | 0M |
| Q2 2025 | 35 | 2M | 17.6% | 8 / 11 | 5 / 5 | 0M | 0M |
| Q1 2025 | 32 | 2M | 19.0% | 3 / 10 | 5 / 3 | 0M | 0M |
| Q4 2024 | 32 | 2M | 19.6% | 6 / 8 | 10 / 5 | 1M | 0M |
| Q3 2024 | 31 | 1M | 10.4% | 4 / 9 | 8 / 11 | 0M | 0M |
| Q2 2024 | 39 | 1M | 10.1% | 11 / 8 | 12 / 6 | 0M | 0M |
| Q1 2024 | 34 | 1M | 8.7% | 10 / 9 | 10 / 6 | 0M | 0M |
| Q4 2023 | 30 | 1M | 9.0% | 3 / 6 | 13 / 0 | 0M | 0M |
| Q3 2023 | 27 | 1M | 9.0% | 3 / 5 | 8 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LTRN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 338,385 | 2.65% | $1.41M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 81,101 | 0.63% | $338.19K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 47,619 | 0.37% | $170.95K | 0.00% | May 31, 2026 |
| Horizon Kinetics Medical ETF | 25,164 | 0.20% | $104.93K | 0.55% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 15,273 | 0.12% | $54.83K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 11,259 | 0.09% | $40.42K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,838 | 0.05% | $24.55K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 4,832 | 0.04% | $20.15K | 0.00% | Jun 30, 2026 |
| Dimensional US Sustainability Core 1 ETF | 1,924 | 0.02% | $5.06K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 643 | 0.01% | $1.69K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Panna Sharma | President & CEO, Director | – | – | Sep 23, 2025 |
| Kishor G. Bhatia | Chief Scientific Officer | – | – | Dec 22, 2025 |
| David R. Margrave | Chief Financial Officer | – | – | Dec 22, 2025 |
| Lee Troy Schalop | Director | 48,544 | 0.38% | May 14, 2026 |
| D. Jeffrey Keyser | Director | 94,303 | 0.74% | May 14, 2026 |
| David S. Silberstein | Director | 1,044,000 | 8.17% | Jan 13, 2026 |
| Vijay Chandru | Director | – | – | Jan 13, 2026 |
| Maria-Luisa Maccecchini | Director | – | – | Jan 13, 2026 |
| BIOS Fund II, LP | 10% owner | 1,883,025 | 14.73% | Jun 13, 2025 |
| BIOS Fund I QP, LP | 10% owner | – | – | Jun 13, 2025 |
| Aaron G.L. Fletcher | 10% owner | 1,233,802 | 9.65% | Jun 13, 2025 |
| BIOS Advisors GP, LLC | 10% owner | 1,177,565 | 9.21% | Jun 13, 2025 |
| BIOS Fund II QP, LP | 10% owner | 1,075,952 | 8.42% | Jun 13, 2025 |
| BIOS Fund II NT, LP | 10% owner | – | – | Jun 13, 2025 |
| Bios Equity Partners, LP | 10% owner | 304,498 | 2.38% | Jun 13, 2025 |
| Leslie W. Kreis | 10% owner | 1,761,146 | 13.78% | Jun 13, 2025 |
| Cavu Management, LP | 10% owner | 1,387,670 | 10.85% | Jun 13, 2025 |
| Cavu Advisors, LLC | 10% owner | 1,115,952 | 8.73% | Jun 13, 2025 |
| BP Directors, LP | 10% owner | 1,075,952 | 8.42% | Jun 13, 2025 |
| BIOS Fund I, LP | 10% owner | 1,115,952 | 8.73% | Jun 13, 2025 |
| Bios Equity Partners II, LP | 10% owner | 1,263,802 | 9.89% | Jun 13, 2025 |
| BIOS Capital Management, LP | 10% owner | – | – | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| D. Jeffrey Keyser Director | May 12, 2026 | Buy | +48,544 | $2.06 | $100.00K | 94,303 |
| Lee Troy Schalop Director | May 12, 2026 | Buy | +48,544 | $2.06 | $100.00K | 48,544 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −7,206 | $3.09 | $22.27K | 189,117 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −1,903 | $3.09 | $5.88K | 49,957 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −4,354 | $3.09 | $13.45K | 114,272 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −12,319 | $3.09 | $38.07K | 323,335 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −14,218 | $3.09 | $43.93K | 373,178 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −7,206 | $3.09 | $22.27K | 189,117 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −14,218 | $3.09 | $43.93K | 373,178 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −1,903 | $3.09 | $5.88K | 49,957 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −4,354 | $3.09 | $13.45K | 114,272 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −12,319 | $3.09 | $38.07K | 323,335 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −18,678 | $3.38 | $63.13K | 335,654 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −2,886 | $3.38 | $9.75K | 51,860 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −21,557 | $3.38 | $72.86K | 387,396 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −6,601 | $3.38 | $22.31K | 118,626 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −10,925 | $3.38 | $36.93K | 196,323 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −2,886 | $3.38 | $9.75K | 51,860 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −21,557 | $3.38 | $72.86K | 387,396 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −6,601 | $3.38 | $22.31K | 118,626 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −18,678 | $3.38 | $63.13K | 335,654 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −10,925 | $3.38 | $36.93K | 196,323 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −293 | $3.40 | $996 | 354,332 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −45 | $3.40 | $153 | 54,746 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −338 | $3.40 | $1.15K | 408,953 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −103 | $3.40 | $350 | 125,227 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −171 | $3.40 | $581 | 207,248 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −338 | $3.40 | $1.15K | 408,953 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −103 | $3.40 | $350 | 125,227 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −293 | $3.40 | $996 | 354,332 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −171 | $3.40 | $581 | 207,248 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −45 | $3.40 | $153 | 54,746 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 409,291 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −2 | $3.40 | $7 | 125,330 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −3 | $3.40 | $10 | 207,419 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 354,625 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −1 | $3.40 | $3 | 54,791 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 409,291 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −2 | $3.40 | $7 | 125,330 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −1 | $3.40 | $3 | 54,791 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 354,625 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −3 | $3.40 | $10 | 207,419 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −3,639 | $3.03 | $11.03K | 207,422 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −6,221 | $3.03 | $18.85K | 354,630 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −961 | $3.03 | $2.91K | 54,792 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −7,180 | $3.03 | $21.76K | 409,296 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −2,199 | $3.03 | $6.66K | 125,332 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −961 | $3.03 | $2.91K | 54,792 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −7,180 | $3.03 | $21.76K | 409,296 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −6,221 | $3.03 | $18.85K | 354,630 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −3,639 | $3.03 | $11.03K | 207,422 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −2,199 | $3.03 | $6.66K | 125,332 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −1,632 | $2.87 | $4.68K | 127,531 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −2,702 | $2.87 | $7.75K | 211,061 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −4,620 | $2.87 | $13.26K | 360,851 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −714 | $2.87 | $2.05K | 55,753 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −5,332 | $2.87 | $15.30K | 416,476 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −714 | $2.87 | $2.05K | 55,753 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −5,332 | $2.87 | $15.30K | 416,476 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −1,632 | $2.87 | $4.68K | 127,531 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bios Fund II NT, LP Affiliate (10% owner) | May 27, 2025 | 25,849 | $85.03K | May 27, 2025 | Conversion of Shares in IPO |
| Bios Fund I QP, LP Affiliate (10% owner) | May 27, 2025 | 29,576 | $97.31K | May 27, 2025 | Conversion of Shares in IPO |
| Bios Fund II, LP Affiliate (10% owner) | May 27, 2025 | 53,454 | $175.86K | May 27, 2025 | Conversion of Shares in IPO |
| Bios Fund I, LP Affiliate (10% owner) | May 27, 2025 | 75,941 | $249.85K | May 27, 2025 | Conversion of Shares in IPO |
| Bios Fund II QP, LP Affiliate (10% owner) | May 27, 2025 | 105,180 | $346.04K | May 27, 2025 | Conversion of Shares in IPO |
| Bios Fund I, LP Affiliate (10% owner) | Apr 26, 2024 | 371,950 | $1.99M | Apr 29, 2024 | Conversion of Shares in IPO |
| Bios Fund II NT, LP Affiliate (10% owner) | Apr 26, 2024 | 54,597 | $291.55K | Apr 29, 2024 | Conversion of Shares in IPO |
| Bios Fund II, LP Affiliate (10% owner) | Apr 26, 2024 | 124,887 | $666.90K | Apr 29, 2024 | Conversion of Shares in IPO |
| Bios Fund II QP, LP Affiliate (10% owner) | Apr 26, 2024 | 407,845 | $2.18M | Apr 29, 2024 | Conversion of Shares in IPO |
| Bios Fund I QP, LP Affiliate (10% owner) | Apr 26, 2024 | 217,553 | $1.16M | Apr 29, 2024 | Conversion of Shares in IPO |
| Bios Fund II, LP Affiliate (10% owner) | Feb 28, 2024 | 30,650 | $119.84K | Feb 27, 2024 | Conversion of Shares in IPO |
| Bios Fund II NT, LP Affiliate (10% owner) | Feb 28, 2024 | 13,417 | $52.46K | Feb 27, 2024 | Conversion of Shares in IPO |
| Bios Fund II QP, LP Affiliate (10% owner) | Feb 28, 2024 | 100,236 | $391.92K | Feb 27, 2024 | Conversion of Shares in IPO |